Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.53 |
| ▸ | BACE1 | P56817 | 5/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1745376 | 1.00 | TTR (0.53) | TTRBACE1AKR1C3HSD17B10APEX1 | |
| SCHEMBL7822855 | 0.84 | GABRA1 (0.56) | AKR1C3APEX1GABRA1GABRG2GABRB3 | |
| SCHEMBL7822858 | 0.84 | GABRA1 (0.56) | AKR1C3APEX1GABRA1GABRG2GABRB3 | |
| SCHEMBL27322404 | 0.83 | AKR1C3 (0.43) | AKR1C3APEX1GABRA1GABRG2GABRB3 | |
| SCHEMBL30532980 | 0.81 | AKR1C3 (0.44) | AKR1C3APEX1KDM4EEGFR | |
| SCHEMBL2393452 | 0.79 | BACE1 (0.50) | TTRBACE1HSD17B10GABRA1GABRG2 | |
| SCHEMBL1416591 | 0.79 | EGFR (0.58) | AKR1C3HSD17B10KDM4EMEN1POLB | |
| SCHEMBL10884046 | 0.78 | AKR1C3 (0.44) | AKR1C3APEX1GABRA1GABRG2GABRB3 | |
| SCHEMBL10884042 | 0.78 | AKR1C3 (0.44) | AKR1C3APEX1GABRA1GABRG2GABRB3 | |
| SCHEMBL14793890 | 0.77 | ALDH1A1 (0.45) | TTRBACE1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757093-B1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
| EP-2757093-A1 | GUANIDINOBENZOIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | TTR 362/4885BACE1 1069/4885AKR1C3 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.